-
Zhongsheng pharmaceutical and Wuxi apptec sign two more technology development contracts
Time of Update: 2015-10-14
Abstract: on July 13, 2015, Zhongsheng Pharmaceutical Co., Ltd and Wuxi apptec signed the strategic cooperation agreement between Guangdong Zhongsheng Pharmaceutical Co., Ltd and Shanghai apptec new d
-
$1 billion! Xinda biology again develops innovative antibody together with Lilly
Time of Update: 2015-10-12
The news that Hengrui pharmaceutical transferred its tumor immune drugs with a maximum of 800 million US dollars has not yet dissipated Another domestic biopharmaceutical R & D enterprise quietly won
-
[global + China] top 20: the most promising new lung cancer drug
Time of Update: 2015-10-10
The golden wind and autumn rain have swept away the heavy haze of the emperor for days, bringing the air quality back to "good" from "heavy pollution" Air quality has a great influence on lung Smoking
-
CDE drug review and analysis report in September 2015
Time of Update: 2015-10-10
In September 2015, CDE undertook 636 new drug registration applications with acceptance number (excluding reexamination, the same below) Figure 1 total acceptance of CDE drugs from January to Septembe
-
Bio 3D printing equipment of printable liver unit comes out to promote the creation and development of new drugs in China
Time of Update: 2015-10-10
On October 9, Xu MingEn, head of the research team and professor of Hangzhou University of Electronic Science and technology, introduced the relevant information of "printing" liver unit "regenovo 3D
-
Behind Tu Youyou's Nobel Prize: Chinese Medicine Approval Now Marginal Risk
Time of Update: 2015-10-09
On the evening of October 5, Sweden's Karolin Medical College announced in Stockholm that it would award the 2015 Nobel Prize in physiology or medicine to Tu Youyou, a Chinese female pharmacist, as we
-
[including Artemisia! 】Sunflower pharmaceutical and Suzhou Yusen signed a new drug technology transfer contract for Xiaoer Haoqin Kanggan granules
Time of Update: 2015-10-09
Sunflower Pharmaceutical Group (Xiangyang) Longzhong Co., Ltd (hereinafter referred to as "Longzhong pharmaceutical" or "party a"), a holding subsidiary of sunflower Pharmaceutical Group, recently tra
-
CDE drug review weekly report (September 26, 2015 to October 7, 2015)
Time of Update: 2015-10-08
In the review this week (2015.9.26-2015.10.7), 15 drugs (calculated by acceptance number) entered the review status Among them, there are 11 chemicals, the most of which is 3.1, 7 in total In addition
-
Application for new drug of risperidone microsphere injection (ly03004) of LVYE pharmaceutical in the United States
Time of Update: 2015-10-08
Green leaf Pharmaceutical Group recently announced that the US Food and Drug Administration (FDA) confirmed that the risperidone microsphere injection (ly03004) developed by the company does not need
-
CDE drug review weekly report (2015.9.21-2015.9.25)
Time of Update: 2015-09-26
During the review this week (2015.9.21-2015.9.25), 93 drugs (based on the acceptance number) entered the review status, with the number almost the same as last week Most of them are chemical drugs, a
-
Hong Kong Li's pharmaceutical company acquires the rights and interests of the new generation of warfarin analogue, techfarin China
Time of Update: 2015-09-25
Warfarin is an old drug for more than 60 years, but it has been the main drug of atrial fibrillation until the new anticoagulant appeared recently However, the drug drug drug interaction of warfarin i
-
CDE drug review weekly report (2015.9.12-2015.9.19)
Time of Update: 2015-09-21
In the review this week (2015.9.12-2015.9.19), 95 drugs (calculated by acceptance number, the same below) entered the review status, 90 chemicals, almost the same as last week, including 6 1.1 categor
-
In the clinical trial of the new drug division of HongRi pharmaceutical sepsis 1.1
Time of Update: 2015-09-18
HongRi Pharmaceutical (300026) said Friday (September 18) that the company's new sepsis class 1.1 drug is currently in clinical trials The main business of HongRi pharmaceutical is the R & D, producti
-
CDE drug review weekly report (2015.9.6-2015.9.12)
Time of Update: 2015-09-14
In the review this week (2015.9.6-2015.9.12), 87 drugs (calculated according to the acceptance number, the same below) entered the review state, 81 chemicals, double the last week, including 3 1.1 cat
-
CDE drug review weekly report (August 29, 2015 to September 5, 2015)
Time of Update: 2015-09-07
In the review this week (2015.8.29-2015.9.5), 42 drugs (calculated according to the acceptance number, the same below) entered the review status, 36 chemicals, 1 / 3 less than last week Among the chem
-
Innovative drug overseas Xinhengrui sells PD-1 monoclonal antibody to Incyte for US$795 million
Time of Update: 2015-09-06
September 7, 2015 - Incyte announced that it has obtained the overseas exclusive R & D and sales right of Jiangsu Hengrui pharmaceutical PD-1 monoclonal antibody shr-1210, which is still in the resear
-
Hengrui pharmaceutical PD-1 project sr1210 gains US $25 million before entering clinical practice
Time of Update: 2015-09-04
On September 3, Hengrui pharmaceutical announced that it would license the PD-1 monoclonal antibody project (sr1210) for tumor immunotherapy with its own intellectual property rights to Incyte company
-
CDE drug review weekly report (August 24, 2015 to August 29, 2015)
Time of Update: 2015-08-31
I during the review this week (August 24, 2015 to August 29, 2015), 57 drugs (calculated according to the acceptance number) entered the review status, 54 chemicals, and the quantity returned, 1 / 3 m
-
CDE Drug Evaluation Weekly Report (2015.8.16-2015.8.23)
Time of Update: 2015-08-25
I in the review of this week (August 16, 2015 to August 23, 2015), 41 drugs (calculated by acceptance number) entered the review status, and 35 chemicals, far less than last week, it seems that the po
-
We should not only attach importance to innovative drugs, but also ignore generic drugs
Time of Update: 2015-08-17
"Generic drugs take longer to review than innovative drugs." Recently, the reporter learned in the interview that the average clinical evaluation time of a generic drug is 3-4 years, and the approval
